Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

NCT02399085 is registered in ClinicalTrials.gov with MorphoSys AG as lead sponsor.

NCT NCT02399085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02399085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
Lead sponsor
MorphoSys AG
Phase
Phase 2
Overall status
Completed
Start date
March 29, 2016
Completion date
April 19, 2023
Enrollment
81 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma